In a female patient with giant‑cell arteritis on high‑dose prednisone, receiving metoprolol and atorvastatin, and currently having a deep wound infection, which laboratory tests and clinical parameters should be monitored and how often?

Monitoring Parameters for Giant Cell Arteritis with Wound Infection on High-Dose Prednisone

In this patient with giant cell arteritis on high-dose prednisone, metoprolol, and atorvastatin who has developed a deep wound infection, you must monitor inflammatory markers (ESR/CRP) weekly during active infection and monthly during steroid taper, complete blood counts every 1–2 weeks until infection resolves, wound cultures to guide antibiotic therapy, blood glucose weekly (prednisone-induced hyperglycemia), electrolytes weekly (hyponatremia risk), and bone density/fracture risk assessment given prolonged steroid exposure.

Inflammatory Markers – Weekly During Infection, Then Monthly

• ESR and CRP should be measured weekly while the wound infection is active, because infection itself elevates these markers and can mask or mimic GCA relapse 1, 2.
• Once the infection resolves, measure ESR/CRP monthly during the steroid taper to distinguish true GCA relapse from isolated marker elevation 1, 2.
• Do not escalate immunosuppression based solely on elevated ESR/CRP without accompanying clinical symptoms (new headache, jaw claudication, visual changes), because isolated marker elevation warrants observation rather than treatment intensification 1, 2.
• ESR >100 mm/h or CRP ≥2.5 mg/dL in the presence of new cranial symptoms indicates GCA relapse and requires immediate steroid dose increase 1.

Complete Blood Count – Every 1–2 Weeks Until Infection Resolves

• Monitor WBC, neutrophils, hemoglobin, hematocrit, and platelets every 1–2 weeks until the wound infection clears 1.
• The patient's current neutrophilia (8.3 × 10⁹/L) and monocytosis (1.5 × 10⁹/L) reflect both the acute bacterial infection and chronic inflammatory disease 1.
• Persistent or worsening leukocytosis despite antibiotic therapy signals inadequate infection control or antibiotic resistance, particularly concerning given the 3+ Enterobacter cloacae (hospital-acquired, multidrug-resistant organism) in the deep wound culture 1.
• The patient's anemia of chronic disease (RBC 3.64, Hgb 114 g/L, Hct 0.34) is expected with GCA but will worsen with ongoing infection; hemoglobin <100 g/L warrants investigation for occult bleeding or bone marrow suppression 1.
• Elevated RDW (18.9%) confirms anemia of chronic disease and will not normalize until both GCA and infection are controlled 1.

Wound Cultures and Infection Surveillance

• Repeat deep wound cultures every 1–2 weeks until cultures are negative or show only colonizing flora, because the current polymicrobial infection (Enterobacter cloacae 3+, Enterococcus faecalis 1+, Streptococcus anginosus 1+, Candida parapsilosis 1+) requires targeted antibiotic therapy 1.
• Enterobacter cloacae is the most concerning organism due to its gram-negative nature, hospital-acquired origin, and frequent multidrug resistance; ensure antibiotic sensitivities guide therapy 1.
• Monitor for new fever, increased wound drainage, expanding erythema, or worsening pain at every visit, as high-dose prednisone (40–60 mg daily) suppresses immune response and masks infection severity 1, 2.

Blood Glucose – Weekly Monitoring

• Check fasting glucose or hemoglobin A1C weekly during high-dose prednisone therapy, because glucocorticoids cause dose-dependent hyperglycemia and the patient is on 40–60 mg daily 1, 2.
• Initiate or adjust diabetes management if fasting glucose exceeds 7.0 mmol/L or random glucose exceeds 11.1 mmol/L, as hyperglycemia impairs wound healing and worsens infection outcomes 1.

Electrolytes – Weekly Until Stable

• Monitor sodium, potassium, and renal function weekly until the patient's hyponatremia (133 mmol/L) resolves 1.
• The current hyponatremia is multifactorial: decreased oral intake, vomiting, and potential SIADH from high-dose glucocorticoids 1.
• Correct sodium cautiously (0.5 mmol/L/hour maximum) to avoid osmotic demyelination syndrome, and ensure adequate nutritional intake to address the low albumin (31 g/L) 1.

Lipid Panel – Every 3 Months

• Repeat lipid profile every 3 months while on prednisone, metoprolol, and atorvastatin, because the patient's low HDL (0.95 mmol/L) and elevated triglycerides (2.07 mmol/L) are worsened by corticosteroid therapy 1.
• Prednisone and metoprolol raise triglycerides by 10–30% depending on dose and duration, though atorvastatin provides partial mitigation 1.

Bone Density and Fracture Risk – Baseline and Annually

• Obtain baseline DEXA scan if not already done, because long-term glucocorticoid therapy (≥3 months at ≥7.5 mg/day prednisone equivalent) causes rapid bone loss 2.
• Initiate bone-protective therapy immediately: calcium 1200–1500 mg daily, vitamin D 800–1000 IU daily, and bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) unless contraindicated 2.
• Repeat DEXA annually while on glucocorticoids to assess fracture risk and treatment efficacy 2.

Clinical Assessment – Every Visit

• At every follow-up, assess for GCA relapse symptoms: new or worsening headache, jaw claudication, visual changes (diplopia, blurred vision, transient vision loss), scalp tenderness, and limb claudication 1, 2.
• Jaw claudication (pain with chewing that resolves with rest) has the highest positive likelihood ratio (4.90) for active GCA and mandates immediate steroid dose increase 1.
• Visual symptoms are a neuro-ophthalmic emergency; if present, administer IV methylprednisolone 500–1000 mg daily for 3 days before transitioning to oral prednisone 1, 2.
• Palpate temporal arteries for thickening, tenderness, or absent pulse at each visit 1.

Vascular Imaging – Baseline and As Needed

• Baseline MR or CT angiography of neck/chest/abdomen/pelvis should have been obtained at GCA diagnosis to assess large-vessel involvement 1, 2.
• Repeat imaging every 6–12 months if large-vessel involvement was documented, to surveil for aneurysms, stenoses, or progression 1, 2.
• Patients without large-vessel involvement do not require routine repeated imaging unless new vascular symptoms develop 1, 2.

Glucocorticoid Tapering Guidance

• Maintain prednisone 40–60 mg daily for 1 month after symptoms resolve and ESR/CRP normalize, then begin gradual taper 1, 2.
• Target dose: 15–20 mg/day by 2–3 months, ≤5 mg/day by 12 months 1, 2.
• Do not taper during active infection; wait until wound cultures are negative and inflammatory markers are stable 1.
• Relapses occur in 34–75% of patients during tapering; if cranial ischemic symptoms recur, immediately increase prednisone to 40–60 mg daily and add tocilizumab 1, 2.

Steroid-Sparing Agents – Consider Now

• Tocilizumab (162 mg subcutaneously weekly) should be added to reduce cumulative glucocorticoid exposure, lower relapse rates, and enable faster tapering 1, 2.
• Methotrexate is an alternative if tocilizumab is contraindicated, though evidence is less robust 1, 2.
• Do not delay tocilizumab initiation; it is most effective when started at diagnosis rather than reserved for relapse management 1, 2.

Common Pitfalls to Avoid

• Do not rely solely on ESR/CRP to guide treatment; clinical symptoms take precedence, especially during active infection when markers are nonspecifically elevated 1, 2.
• Do not taper prednisone while the wound infection is active; immunosuppression must be balanced against infection control 1.
• Do not ignore isolated marker elevation without symptoms; observe and recheck in 1–2 weeks rather than escalating therapy 1, 2.
• Do not forget bone protection; glucocorticoid-induced osteoporosis occurs rapidly and is preventable 2.